Changing the way drugs are developed and delivered can have a positive impact for patients and caregivers. Aquestive Therapeutics is the primary innovator and worldwide leader in developing medicines on oral films to maximize their usability.
Independently and with partners, our quest is to leverage our highly customizable PharmFilm® technology to solve therapeutic problems and meaningfully improve the lives of people who face barriers to using important medications.
PharmFilm® is a unique and versatile technology for high-performance drug delivery. Aquestive scientists combine the customizable features of PharmFilm® with patented formulation and engineering processes to optimize the delivery of active pharmaceutical ingredients (APIs).
PharmFilm® technology provides the development platform for our expanding pipeline of proprietary and partner-developed products.
Sublingual, lingual, or buccal drug delivery gives patients with complex dosing challenges a simple, non-invasive, and more convenient way to dose. No mixing, swallowing, or chewing.1 The degree of mucosal permeability and desired product profile are used to determine the targeted route of delivery. In this way, Aquestive’s Development Services team can tailor treatments to optimize a drug’s pharmacokinetic profile and meet the requirements of specific patient populations.
Controlled release and engineered retention time in a controlled microenvironment
Rapid onset of action with direct entry into systemic circulation
Rapid disintegration and controlled release with bioequivalancy to tablets and capsules
Polymers are used as film formers to hold the API and excipients in place.
Patented techniques are used to ensure that the API is uniformly distributed throughout the film.
Aquestive utilizes the proprietary features of PharmFilm® technology along with a wide array of solvents, pH modifiers, and permeation enhancers to achieve target absorption, bioavailability, and onset of action.
Deep understanding of oral mucosa allows for tailored absorption profiles.
Novel use of solvent systems, permeation enhancers, stabilizers, and polymer blends ensures consistent and reproducible delivery of active ingredients.
Film designs are customized to maximize transcellular and/or intercellular transport across the buccal mucosa.
Upon application to the mucosa, our PharmFilm® medicines begin to dissolve. APIs or proteins are released at a rate determined by the proprietary compositional profile created during formulation.
Every medicine is different, so Aquestive follows a drug-by-drug approach for harnessing film technology to achieve target product profiles and clinical improvement goals. Customized to the chemical structure of the API, the Formulation Engineering team leverages proprietary PharmFilm® technologies, pH modifiers, and permeation enhancers to achieve target absorption.
Customized film designs maximize transcellular and intercellular transport across the mucosa
Expertise in applying pH modifiers and permeation enhancers for targeted absorption
Expert scientists tailor blends of polymers, prodrugs, and excipients to optimize drug release and bioavailability
The compositional profile of the custom formulation is used to establish the optimal rate of dissolution
Unique polymer blends hold the API and excipients in place, preserving the original structure
Patented techniques are applied to ensure uniform distribution
Adaptable polymer matrix
Array of FDA-approved permeation enhancers
Variety of flavors
Range of drug loads
1. Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015;(75):2-9.